Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Net Cash Flow: 2023-2025

Historic Net Cash Flow for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to $71.5 million.

  • Zenas BioPharma's Net Cash Flow fell 59.39% to $71.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$244.4 million, marking a year-over-year decrease of 184.93%. This contributed to the annual value of $262.7 million for FY2024, which is 2619.00% up from last year.
  • As of Q3 2025, Zenas BioPharma's Net Cash Flow stood at $71.5 million, which was up 146.97% from -$152.3 million recorded in Q2 2025.
  • Zenas BioPharma's 5-year Net Cash Flow high stood at $176.2 million for Q3 2024, and its period low was -$152.3 million during Q2 2025.
  • In the last 3 years, Zenas BioPharma's Net Cash Flow had a median value of -$17.5 million in 2023 and averaged $5.4 million.
  • Data for Zenas BioPharma's Net Cash Flow shows a maximum YoY tumbled of 524.31% (in 2025) over the last 5 years.
  • Over the past 3 years, Zenas BioPharma's Net Cash Flow (Quarterly) stood at -$15.3 million in 2023, then slumped by 163.43% to -$40.4 million in 2024, then slumped by 59.39% to $71.5 million in 2025.
  • Its last three reported values are $71.5 million in Q3 2025, -$152.3 million for Q2 2025, and -$123.2 million during Q1 2025.